Page Loading

Pharma firm Piramal scales up manufacturing operations in Scotland with expansion of its Grangemouth site

19 Dec 2023 • 5 minute read

Learn more about the expansion of Piramal’s Grangemouth facility.

The event marked the completion of Piramal’s £45 million investment into Scotland’s life sciences sector, creating and safeguarding high-quality jobs.

The ambitious project – which has increased the site’s manufacturing capacity by more than 70% – was supported by a £2.4 million R&D grant from Scottish Enterprise.  

Representatives from Scottish Enterprise and Piramal gathered at the site in December 2023 to celebrate the opening of the expanded facility and the scaling opportunities it represents.

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organisation in the pharmaceutical industry. Part of Piramal Pharma Ltd, PPS is a global leader in the development and manufacturing of antibody-drug conjugate (ADC), which is used in the treatment of cancers.

An expanded site with over double the capacity

The Grangemouth site previously had three ADC manufacturing suites. The expansion has added a further two start-of-the-art suites specifically designed to complement the existing ones.

These will enhance the site’s current capacity by approximately seventy to eighty percent, enabling the scale up of commercial ADC manufacturing batches.

The site expansion also includes a dedicated customer experience centre for clients who are visiting the site during development or manufacturing activities, along with new Quality Control laboratories, warehousing and office space, and supporting utilities.

The building has been designed to accommodate further expansion. Potential future enhancements could include a new sterile fill and finish suite dedicated to ADCs, and two additional large-scale manufacturing suites capable of handling increased batch sizes.

End-to-end manufacturing from Grangemouth

The expansion of the site will enhance its ability to deliver the full life cycle of ADC development and manufacturing.

This integrated offering combines the development of the monoclonal antibody, linker/payload, conjugation, and sterile fill and finish into a single integrated program across four global Piramal sites, including Grangemouth.

The approach simplifies development and manufacturing, speeding the process by which new compounds can get to the patients who need them. Programs such as ADCelerate, coupled with the highly skilled workforce in Grangemouth, exemplify how Piramal brings the best science to its customers and their patients.

Support from Scottish Enterprise 

The commissioning of the expanded facility represents the culmination of a £45 million investment to support the rapidly growing demand for ADC manufacturing.

Scottish Enterprise supported the expansion with a £2.4 million grant. Adrian Gillespie, Chief Executive of Scottish Enterprise, commented that “Piramal’s welcome £45 million investment into Scotland’s life sciences sector would create and safeguard high-quality jobs."

Wellbeing Economy Secretary Neil Gray added that the “investment in pharmaceutical innovation helps build on Scotland’s strengths in health and life sciences, creating new jobs and opportunities as part of a fair and growing wellbeing economy. It also augments Grangemouth’s heritage as a critical manufacturing hub for Scotland”.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.

PPS offers a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. 

You might also be interested in

  • Eurostampa expanding operations with North Lanarkshire facility

    Find out more about international packaging firm Eurostampa and its multi-million-pound investment in a new Cumbernauld facility.

  • Inward investment continues to deliver for Scotland

    Read about our new figures, which show that inward investment has secured thousands of jobs in Scotland over the last year.

  • Digital skills support for businesses locating in Scotland

    Discover how Scotland's digital talent can benefit your business, wherever you are in the world.

Get the latest updates from Scotland

Got a question?

We’re always ready to help. Send us an enquiry, or give us a call.